Celgene Revenue

Celgene revenue was $15.28 b in FY, 2018

Embed Graph

Summary - Funding Rounds

Founding Date

1986
Celgene is a subsidiary of Bristol-Myers Squibb

Celgene Income Statement

Annual

USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

3.6b4.8b5.5b6.5b7.7b9.3b11.2b13.0b15.3b

Revenue growth, %

18%21%21%

Cost of goods sold

306.5m425.9m299.1m340.4m385.9m420.1m438.0m461.0m587.0m

Gross profit

3.3b4.4b5.2b6.2b7.3b8.8b10.8b12.5b14.7b

Gross profit Margin, %

92%91%95%95%95%95%96%96%96%

R&D expense

121.2m1.6b1.7b5.9b5.7b

General and administrative expense

950.6m1.2b1.4b2.9b3.3b

Operating expense total

2.2b2.8b3.3b7.8b9.5b

EBIT

989.6m1.4b1.7b1.8b2.5b2.3b3.2b4.7b5.2b

EBIT margin, %

27%30%32%28%33%24%28%36%34%

Interest expense

12.6m42.7m63.2m91.6m176.1m310.6m500.1m

Interest income

44.8m25.9m15.3m105.0m45.0m

Investment income

(1.9m)(2.8m)

Pre tax profit

1.4b1.7b1.7b2.3b2.0b2.4b4.3b4.8b

Income tax expense

132.4m102.1m225.3m215.5m327.5m421.5m373.3m1.4b786.0m

Net Income

880.5m1.3b1.5b1.4b2.0b1.6b2.0b2.9b4.0b

Quarterly

USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

791.3m852.7m910.1m1.1b1.2b1.2b1.3b1.4b1.4b1.5b1.6b1.7b1.7b1.9b2.0b2.1b2.3b2.3b2.5b2.8b3.0b3.0b3.3b3.3b3.5b3.8b3.9b4.0b4.4b4.5b

Cost of goods sold

61.9m68.0m63.5m127.3m126.4m94.6m72.5m71.9m74.6m80.5m80.9m86.2m86.1m98.9m97.7m104.0m100.8m109.9m105.9m110.9m107.7m113.0m111.0m118.0m135.0m126.0m157.0m140.0m151.0m167.0m

Gross profit

729.3m784.7m846.6m998.0m1.1b1.2b1.2b1.3b1.3b1.4b1.5b1.6b1.6b1.8b1.9b2.0b2.2b2.2b2.4b2.6b2.9b2.8b3.2b3.2b3.4b3.7b3.7b3.9b4.2b4.4b

Gross profit Margin, %

92%92%93%89%89%92%94%95%95%95%95%95%95%95%95%95%96%95%96%96%96%96%97%96%96%97%96%97%97%96%

R&D expense

204.7m121.2m253.5m435.5m371.5m356.8m362.0m447.1m441.6m452.4m458.1m584.5m713.7m456.9m675.1m506.0m1.1b1.3b733.2m948.7m1.7b995.0m835.0m1.3b2.2b1.3b1.1b1.2b1.1b1.2b

General and administrative expense

208.0m219.3m228.3m302.3m305.6m303.3m325.8m323.0m354.6m369.0m418.1m448.7m494.1m491.8m497.6m616.8m550.3m543.0m732.1m698.0m620.0m939.0m608.0m864.0m790.0m746.0m773.0m793.0m781.0m

Operating expense total

459.1m616.9m535.9m710.0m737.8m724.0m718.5m853.6m843.0m920.3m954.4m1.1b1.3b1.0b1.2b1.1b1.8b2.1b1.4b1.8b2.5b1.7b1.8b2.1b3.2b2.2b2.1b2.2b2.1b2.1b

Depreciation and amortization

84.0m

EBIT

270.2m167.8m310.7m288.0m318.9m431.1m482.3m441.4m501.6m463.8m563.7m455.6m361.8m758.9m646.6m859.0m415.8m79.6m1.0b823.7m411.5m1.1b1.3b1.1b218.0m1.5b1.7b1.7b2.1b2.3b

EBIT margin, %

34%20%34%26%27%34%38%32%35%32%35%27%21%41%33%41%18%3%40%30%14%38%40%33%6%39%43%42%48%50%

Interest expense

481.0k426.0k414.0k11.8m9.4m10.3m11.4m11.5m17.8m17.9m19.6m

Interest income

14.1m10.1m12.8m4.5m5.9m8.5m3.7m3.1m2.7m4.8m4.5m5.3m6.4m7.3m6.9m9.0m8.8m8.6m6.8m7.2m7.3m15.0m24.0m33.0m13.0m9.0m8.0m34.0m38.0m45.0m

Investment income

103.0k(1.4m)556.0k(1.3m)(1.7m)1.2m

Pre tax profit

318.4m412.6m474.0m440.7m476.5m448.4m557.8m442.0m332.3m706.8m577.5m827.1m470.8m(19.9m)921.6m695.1m256.8m1.0b1.1b991.0m1.0b1.3b1.4b1.8b1.8b1.9b

Income tax expense

53.9m16.9m49.0m31.7m39.2m39.7m72.5m73.3m52.3m63.5m79.7m69.5m52.6m109.0m69.0m108.2m114.6m14.2m120.9m96.9m85.4m84.0m69.0m3.0m184.0m262.0m296.0m269.0m250.0m226.0m

Net Income

234.4m155.4m281.2m255.6m279.4m373.0m401.5m367.4m424.2m384.9m478.1m372.5m279.7m597.8m508.5m718.9m356.2m(34.1m)800.7m598.2m171.4m941.0m1.1b988.0m846.0m1.0b1.1b1.5b1.6b1.7b

Celgene Balance Sheet

Annual

USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.4b1.9b2.1b3.2b4.1b4.9b6.2b7.0b4.2b

Accounts Receivable

706.4m945.5m960.5m1.9b2.1b

Prepaid Expenses

275.0m395.1m320.2m388.0m501.0m

Inventories

260.1m189.6m259.5m340.4m393.1m443.4m497.9m541.0m458.0m

Current Assets

4.3b4.4b5.5b7.6b9.7b9.4b10.9b14.9b9.1b

PP&E

509.9m506.0m578.4m593.4m642.6m814.1m929.8m1.1b1.4b

Goodwill

1.9b1.9b2.0b2.0b2.2b4.9b4.9b4.9b

Total Assets

10.2b10.0b11.7b13.4b17.3b27.1b28.1b30.1b35.5b

Accounts Payable

94.5m121.5m145.7m156.2m198.2m240.8m247.1m305.0m418.0m

Short-term debt

392.4m526.7m308.5m544.8m605.9m500.7m501.0m

Current Liabilities

1.1b1.5b1.7b1.9b2.1b2.0b3.0b3.0b4.1b

Long-term debt

1.2b1.3b2.8b15.8b19.8b

Total Debt

1.6b1.8b3.1b544.8m605.9m500.7m15.8b501.0m

Total Liabilities

4.2b4.5b6.0b23.2b29.3b

Common Stock

4.8m4.9m5.0m10.0m10.0m

Preferred Stock

Additional Paid-in Capital

6.4b6.8b7.5b8.7b9.8b11.1b12.4b13.8b15.0b

Retained Earnings

248.3m1.6b3.0b4.5b6.5b8.1b10.1b13.1b17.6b

Total Equity

6.0b5.5b5.7b5.6b6.5b5.9b6.6b287.0m(50.0m)

Debt to Equity Ratio

0.1 x0.1 x0.1 x-10 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.7 x1.8 x2.1 x2.4 x2.7 x4.6 x4.3 x105 x-709.6 x

Quarterly

USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

1.1b855.6m2.8b1.5b1.6b1.8b1.9b1.9b2.7b1.5b1.7b2.4b2.4b3.2b3.7b4.4b4.5b6.0b4.4b5.1b5.5b5.3b6.7b5.5b2.8b1.5b2.5b5.4b7.2b9.6b

Accounts Receivable

481.1m477.4m593.1m804.0m863.0m888.2m1.0b884.9m957.5m1.0b1.0b1.1b1.1b1.1b1.2b1.3b1.3b1.4b1.5b1.6b1.6b1.7b1.8b2.0b2.1b2.1b2.3b2.5b2.4b

Prepaid Expenses

312.1m303.4m240.7m246.0m271.5m242.9m322.7m275.1m224.5m385.0m442.3m387.8m386.1m382.6m509.4m774.6m692.4m703.9m787.8m760.0m612.8m633.0m734.0m671.0m605.0m824.0m819.0m521.0m445.0m732.0m

Inventories

102.5m100.8m108.7m223.2m196.4m187.5m215.6m223.2m235.9m275.4m294.4m313.3m347.8m360.0m372.0m386.7m414.3m420.9m470.6m490.4m507.9m509.0m533.0m537.0m536.0m555.0m510.0m442.0m464.0m451.0m

Current Assets

3.9b4.1b4.5b4.2b4.3b4.1b4.0b4.1b5.4b5.3b5.9b7.6b6.9b8.1b8.8b9.7b9.9b10.2b8.4b9.2b9.6b11.6b13.1b14.8b7.9b6.9b7.8b11.0b12.7b14.5b

PP&E

303.7m309.4m318.7m517.0m472.7m490.2m519.1m526.8m547.4m578.2m584.9m592.3m595.7m605.1m623.6m649.7m675.2m702.0m840.0m854.0m891.3m958.0m989.0m1.0b1.3b1.3b1.3b1.4b1.4b1.4b

Goodwill

764.6m764.6m763.6m1.9b1.9b1.9b2.0b2.0b2.0b2.0b2.0b2.0b2.0b2.2b2.2b2.2b2.2b4.7b4.9b4.9b4.9b4.9b4.9b4.9b8.0b8.0b8.0b8.0b8.0b8.0b

Total Assets

6.0b6.2b6.6b9.8b10.1b9.8b10.3b10.4b11.6b11.5b12.0b13.6b12.7b15.6b16.4b17.5b17.7b27.4b26.0b26.6b26.8b28.8b30.3b31.7b34.6b33.4b34.2b37.6b39.2b41.4b

Accounts Payable

66.7m67.0m49.9m99.5m99.7m98.4m100.4m109.0m110.4m116.8m142.0m139.6m149.4m184.5m196.7m204.0m204.9m189.4m219.7m229.8m235.4m240.0m272.0m263.0m320.0m294.0m292.0m340.0m327.0m421.0m

Short-term debt

(277.0m)(323.9m)461.7m532.1m269.1m150.5m390.4m324.9m362.0m887.8m405.9m869.8m192.3m100.0m504.4m1.4b1.2b501.0m500.0m500.0m1.4b1.5b502.0m500.0m1.5b

Current Liabilities

459.4m473.4m743.6m1.0b1.1b1.2b1.1b1.4b1.4b1.6b2.3b1.9b2.4b1.5b1.4b2.1b3.0b3.1b1.8b2.0b2.6b2.6b3.2b4.0b3.1b4.5b3.7b4.0b3.7b5.0b

Long-term debt

1.2b1.3b1.3b1.3b1.3b2.8b2.8b2.7b4.2b4.2b6.7b6.7b6.3b6.3b14.3b14.3b14.3b13.8b13.8b13.8b12.9b20.3b19.8b19.7b19.8b19.8b18.3b

Total Debt

(277.0m)(323.9m)1.7b1.8b1.5b1.4b1.7b3.1b3.1b3.6b405.9m869.8m192.3m100.0m504.4m1.4b1.2b14.3b14.3b501.0m500.0m500.0m1.4b20.3b1.5b502.0m500.0m19.8b1.5b

Total Liabilities

1.2b1.3b1.4b4.0b4.1b4.2b4.3b4.4b5.9b5.9b6.6b7.7b8.2b10.8b10.6b10.7b11.4b22.0b20.9b21.0b21.1b21.2b21.9b21.9b29.4b30.0b29.4b29.5b29.1b29.3b

Common Stock

4.7m4.7m4.7m4.8m4.8m4.9m4.9m4.9m5.0m5.0m5.1m5.1m5.1m9.2m9.2m9.3m9.3m9.4m9.4m9.5m9.5m10.0m10.0m10.0m10.0m10.0m10.0m10.0m10.0m10.0m

Preferred Stock

Additional Paid-in Capital

5.5b5.6b5.6b6.4b6.5b6.6b7.1b7.1b7.3b7.6b8.2b8.5b8.9b9.2b9.4b10.2b10.5b10.8b11.4b11.7b12.0b12.7b13.2b13.6b14.1b13.8b14.8b15.4b15.8b16.1b

Retained Earnings

(397.8m)(242.5m)38.7m503.9m783.3m1.2b2.0b2.3b2.8b3.4b3.9b4.3b4.8b5.4b5.9b7.2b7.5b7.5b8.9b9.5b9.6b11.0b12.1b13.1b14.4b15.4b16.5b19.1b20.7b22.4b

Total Equity

4.8b4.9b5.1b5.9b6.0b5.6b6.1b6.0b5.7b5.6b5.4b5.9b4.5b4.9b5.8b6.8b6.3b5.4b5.1b5.5b5.7b410.0m237.0m337.0m(328.0m)(119.0m)(77.0m)(32.0m)(56.0m)(27.0m)

Debt to Equity Ratio

0.1 x0.2 x0 x0 x0.1 x0.2 x0.2 x0.1 x1.2 x2.1 x4.2 x-12.6 x-6.5 x-15.6 x-55.5 x

Debt to Assets Ratio

0 x0.1 x0 x0 x0 x0.1 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1.3 x1.3 x1.3 x1.7 x1.7 x1.7 x1.7 x1.7 x2 x2.1 x2.2 x2.3 x2.8 x3.2 x2.8 x2.6 x2.8 x5.1 x5.1 x4.8 x4.7 x70.3 x127.9 x94.2 x-105.4 x-281 x-444.4 x-1.2 k x-699.7 x-1.5 k x

Celgene Cash Flow

Annual

USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

880.5m1.3b1.5b1.4b2.0b1.6b2.0b2.9b4.0b

Depreciation and Amortization

54.2m71.2m84.9m471.0m635.0m

Accounts Receivable

(234.5m)(263.1m)(30.1m)(101.4m)(166.3m)(304.7m)(222.4m)(236.0m)(178.0m)

Inventories

18.7m71.0m(69.7m)(89.7m)(56.5m)(50.6m)(55.3m)(42.0m)82.0m

Accounts Payable

51.6m223.8m68.2m273.0m290.0m

Cash From Operating Activities

1.2b1.8b2.0b2.2b2.8b2.5b4.0b5.2b5.2b

Purchases of PP&E

(98.6m)(132.1m)(111.5m)(279.0m)(330.0m)

Capital Expenditures

(119.7m)(150.3m)(286.3m)(236.2m)

Cash From Investing Activities

(2.1b)377.7m(1.6b)(528.6m)(1.4b)(6.3b)(1.0b)(2.9b)(6.4b)

Short-term Borrowings

(1.4b)(4.7b)(5.7b)

Long-term Borrowings

(513.9m)(1.9b)

Cash From Financing Activities

1.2b(1.7b)(248.7m)(553.7m)(417.4m)4.6b(1.6b)(1.6b)(1.5b)

Net Change in Cash

249.0m508.3m230.9m843.0m(2.8b)

Interest Paid

1.8m2.3m48.4m90.8m196.2m243.3m527.2m539.0m689.0m

Income Taxes Paid

122.0m93.0m469.6m291.9m294.6m361.1m373.0m475.0m1.2b

Free Cash Flow

2.3b3.0b2.8b4.2b

Quarterly

USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

234.4m389.8m670.9m255.6m535.0m907.3m401.5m768.9m1.2b384.9m863.0m1.2b279.7m877.5m1.4b718.9m1.1b1.0b800.7m1.4b1.6b941.0m2.0b3.0b846.0m1.9b3.0b1.5b3.1b4.8b

Depreciation and Amortization

53.8m25.5m38.9m17.3m35.0m53.1m18.6m38.5m59.9m23.2m47.4m71.8m25.5m52.1m78.1m28.1m57.8m86.6m29.2m58.5m89.6m32.0m66.0m355.0m126.0m296.0m465.0m157.0m94.0m142.0m

Accounts Receivable

54.4m(73.0m)(158.9m)(76.1m)(126.2m)(188.5m)(79.3m)37.4m(34.6m)(87.0m)(74.8m)(138.7m)(9.8m)(61.8m)(46.0m)(59.5m)(140.9m)(145.8m)23.1m(80.7m)(143.8m)17.0m(75.0m)(139.0m)(47.0m)(157.0m)(225.0m)(271.0m)(385.0m)(331.0m)

Inventories

233.0k927.0k(6.4m)40.8m65.4m73.8m(25.5m)(34.0m)(46.3m)(25.8m)(45.2m)(62.6m)(7.0m)(19.1m)(33.6m)7.3m(19.2m)(27.1m)(25.6m)(45.2m)(62.3m)(10.0m)(32.0m)(37.0m)6.0m(14.0m)31.0m16.0m(5.0m)7.0m

Accounts Payable

89.6m(97.4m)(35.6m)90.3m(74.5m)(71.0m)88.4m(82.3m)97.5m150.7m111.5m(20.1m)74.3m59.2m76.8m256.2m55.0m163.9m(365.0m)219.0m28.0m(219.0m)(144.0m)(66.0m)(28.0m)71.0m84.0m

Cash From Operating Activities

284.7m595.1m976.7m275.3m736.4m1.3b310.5m947.4m1.5b367.3m1.1b1.7b557.1m1.1b2.0b856.5m1.1b1.4b974.9m1.9b2.6b853.0m2.5b3.6b(325.0m)904.0m2.8b1.5b3.6b5.8b

Purchases of PP&E

(18.9m)(40.2m)(59.1m)(23.2m)(53.0m)(90.6m)(28.1m)(59.2m)(81.9m)(25.4m)(61.3m)(93.1m)(24.7m)(61.4m)(100.9m)(42.3m)(95.0m)(145.5m)(59.6m)(103.3m)(169.8m)(62.0m)(132.0m)(176.0m)(88.0m)(168.0m)(232.0m)(69.0m)(129.0m)(197.0m)

Cash From Investing Activities

(363.6m)(776.2m)797.2m275.6m169.5m312.0m(6.4m)(350.0m)(778.1m)(251.5m)(526.9m)(1.4b)(220.1m)(1.2b)(1.4b)338.0m239.7m(5.9b)(110.2m)(185.6m)(298.0m)(1.7b)(1.6b)(4.0b)(5.7b)(5.8b)(5.8b)(295.0m)(338.0m)(201.0m)

Short-term Borrowings

(135.7m)(1.4b)(2.8b)(4.1b)(1.4b)(2.6b)(3.7b)(1.1b)(2.6b)(2.9b)(189.6m)(209.7m)(1.6b)(500.0m)(1.8b)(3.9b)(5.7b)

Long-term Borrowings

(500.0m)(500.0m)

Cash From Financing Activities

43.9m(44.5m)(40.3m)(426.9m)(624.3m)(1.2b)(310.1m)(592.4m)156.3m(687.4m)(899.0m)103.7m(1.2b)110.0m(65.9m)(908.1m)(951.3m)6.4b(1.3b)(1.5b)(1.7b)(109.0m)(424.0m)(292.0m)1.8b(643.0m)(1.6b)26.0m(321.0m)(219.0m)

Net Change in Cash

(46.6m)(246.6m)1.7b135.9m296.9m443.8m1.6m3.0m856.1m(594.8m)(348.1m)332.6m(837.8m)(14.9m)508.1m246.1m409.2m1.9b(434.8m)183.4m642.3m(897.0m)490.0m(659.0m)(4.2b)(5.5b)(4.5b)1.2b3.0b5.4b

Interest Paid

2.0m2.0m959.0k24.5m25.0m22.3m45.8m67.4m52.2m75.9m126.2m50.2m120.2m171.1m200.9m264.8m463.3m198.0m262.0m461.0m190.0m300.0m581.0m281.0m390.0m671.0m

Income Taxes Paid

40.5m83.3m115.3m33.0m66.7m79.2m85.4m172.4m369.6m76.6m154.8m226.2m96.6m193.4m275.0m106.7m247.2m345.6m102.1m227.1m345.1m128.0m333.0m450.0m387.0m786.0m974.0m275.0m331.0m503.0m

Celgene Ratios

USDQ1, 2010

Financial Leverage

1.3 x

Celgene Operating Metrics

FY, 2016

Active Clinical Studies

52

Celgene Employee Rating

4539 votes
Culture & Values
4
Work/Life Balance
3.9
Senior Management
3.3
Salary & Benefits
4.2
Career Opportunities
3.5
Source